Portopulmonary hypertension

Rodrigo Cartin-Ceba, Michael J. Krowka

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Portopulmonary hypertension (POPH) is the presence of pulmonary arterial hypertension in patients with portal hypertension. Among liver transplant (LT) candidates, reported incidence rates of POPH range from 4.5% to 8.5%. In patients with LT, intraoperative death and immediate post-LT mortality are feared clinical events when transplantation is attempted in the setting of untreated, moderate to severe POPH; therefore, POPH precludes LT unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function optimized. Specific pulmonary artery vasodilator medications seem effective in reducing pulmonary artery pressures and improving right ventricular function and survival.

Original languageEnglish (US)
Pages (from-to)421-438
Number of pages18
JournalClinics in liver disease
Issue number2
StatePublished - May 2014


  • Cirrhosis
  • Liver transplant
  • Portal hypertension
  • Portopulmonary hypertension
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Portopulmonary hypertension'. Together they form a unique fingerprint.

Cite this